DoJ Claims J&J Paid Kickbacks To Pharmacy To Boost Risperdal Use In Nursing Homes
This article was originally published in The Pink Sheet Daily
Executive Summary
The complaint says J&J paid Omnicare rebates to intervene in physician prescribing and sought to keep "best prices" down by substituting rebate payments for the purchase of Omnicare data.
You may also be interested in...
Medco Health Solutions Faces Second DoJ Probe In Five Years; Latest Involves AstraZeneca
Medco Health Solutions and AstraZeneca have received subpoenas from the DoJ for information involving arrangements pertaining to four AstraZeneca drugs.
Medco Health Solutions Faces Second DoJ Probe In Five Years; Latest Involves AstraZeneca
Medco Health Solutions and AstraZeneca have received subpoenas from the DoJ for information involving arrangements pertaining to four AstraZeneca drugs.
AstraZeneca's Seroquel Settlement With DoJ Is Fourth Targeting Antipsychotic Off-Label Promotion; Firm Avoids Criminal Charges
AstraZeneca's level of cooperation with the Department of Justice's investigation into allegations of off-label promotion for its antipsychotic Seroquel (quetiapine) may have helped shape the final $520 million civil settlement